Pfizer becomes the latest customer of Benchware Discovery 360

As a part of the agreement, Pfizer will license to Tripos certain rights to its internally-developed discovery informatics system, RGate, and Tripos will extend capabilities within D360 to accommodate Pfizer’s unique requirements. D360 will provide a leading technology to Pfizer scientists, while leveraging investment in their legacy system to reduce cost and create a modern, best-of-breed platform for drug discovery and development.

D360 is used by discovery scientists in major pharmaceutical organizations to provide robust data access and analysis capabilities including full-featured, forms-based queries and browsing, a data access dashboard for fast, simple access to data searches, and a wide range of user-requested data analysis functionality.

“Tripos is thrilled that Pfizer has selected D360 as the tool of choice for its worldwide discovery organization,” said Patrick Flanagan, Tripos’ Chief Operating Officer. “D360 accelerates drug discovery and development projects by increasing the ability to access, analyze, and share knowledge throughout worldwide discovery teams. Additionally, this agreement incorporates and extends the best of Pfizer’s existing RGate technology.”